AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Phenylketonuria

Recent research efforts aimed at curing Phenylketonuria.

Last updated

Phenylketonuria

Overview

Phenylketonuria (PKU), also called phenylalanine hydroxylase (PAH) deficiency, is an inherited metabolic condition in which the liver cannot adequately convert the amino acid phenylalanine (Phe) into tyrosine. Phe then accumulates to levels that can harm the developing and adult brain. PKU is usually detected through newborn blood-spot screening; when treatment begins promptly and blood Phe is well controlled, most people have normal intelligence and can lead independent lives, although subtle cognitive, neurologic, and mental-health effects may still occur. GeneReviews: PAH deficiency Nature Reviews Disease Primers: PKU (ncbi.nlm.nih.gov)

There is no approved cure. Standard care is lifelong individualized Phe restriction, Phe-free medical protein supplementation, regular blood monitoring, and specialist metabolic care. Some people can also use sapropterin, the newly approved PAH activator sepiapterin, or pegvaliase, an injected enzyme that breaks down Phe; these treatments reduce Phe but do not repair the underlying PAH gene defect. GeneReviews: PAH deficiency FDA: SEPHIENCE approval snapshot (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been highly active and is centered on restoring PAH activity in liver cells through one-time gene addition, permanent gene editing, or repeat-dose messenger RNA (mRNA) replacement. The field has moved from convincing mouse studies into early human gene-transfer trials, but no genetic therapy has yet demonstrated the long-term safety, durability, and diet-independent metabolic control required to call it a cure in people. State-of-the-art gene therapy review GeneReviews: PAH deficiency (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Liver-directed gene addition. A principal strategy is to deliver a working human PAH gene to hepatocytes, the liver cells that normally process Phe, using an adeno-associated virus (AAV) vector. In a 2021 mouse study, an Anc80 AAV carrying a codon-optimized PAH gene produced a substantial, durable fall in circulating Phe, approaching control values in male mice, without major liver pathology at the doses studied. Anc80 AAV gene replacement in PKU mice (pubmed.ncbi.nlm.nih.gov) This is a meaningful proof of concept, but animal “cures” cannot establish human durability, immune safety, or the ability to re-dose treatment.

Precise gene editing. Two 2023 studies reported especially striking preclinical results for common disease-causing PAH variants. In humanized mouse models carrying the common p.Arg408Trp variant, an adenine base editor delivered as mRNA in lipid nanoparticles corrected liver DNA sufficiently to normalize blood Phe within 48 hours. mRNA–lipid nanoparticle base editing (pubmed.ncbi.nlm.nih.gov) A separate study used AAV-delivered prime editing to correct the same variant, reaching up to 52% whole-liver corrective editing and complete normalization of blood Phe in mice. AAV prime editing of PKU variant (pubmed.ncbi.nlm.nih.gov) These approaches are potentially curative because they aim to fix DNA rather than continuously compensate for the missing enzyme, but they remain preclinical and would need separate designs for many different PAH variants.

mRNA replacement. Instead of changing DNA, mRNA therapies give liver cells temporary instructions to make functional PAH protein. Arcturus researchers showed that lipid-nanoparticle delivery of human PAH mRNA restored Phe metabolism in the Pahenu2 mouse model, while other mouse work found that repeated injections of PAH mRNA reduced Phe in blood, liver, and brain. Arcturus PAH-mRNA study PAH mRNA rescue in mice (pubmed.ncbi.nlm.nih.gov) Moderna has also published preclinical pharmacology and human dose-prediction work for mRNA-3210, its investigational PKU mRNA therapy. Moderna mRNA-3210 preclinical study (pubmed.ncbi.nlm.nih.gov) This strategy may avoid permanent genome changes, but its temporary effect means repeat administration would probably be necessary.

Improved disease control is also advancing, although it is not a cure. Sepiapterin increases availability of the PAH cofactor tetrahydrobiopterin and can improve residual PAH function in responsive people. In the phase 3 APHENITY trial, responsive participants receiving sepiapterin had a mean 63% reduction in blood Phe over six weeks, compared with a 1% increase on placebo; the U.S. Food and Drug Administration approved sepiapterin as SEPHIENCE on July 28, 2025, for responsive patients aged one month and older alongside a Phe-restricted diet. APHENITY phase 3 trial FDA: SEPHIENCE approval snapshot (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

As of October 26, 2026, clinical gene-transfer programs remain early-stage. BioMarin’s BMN 307 is a phase 1/2, open-label AAV-mediated PAH gene-transfer study in adults; the registry lists it as active but not recruiting, with no posted efficacy results. BMN 307 trial record (clinicaltrials.gov) NGGT (Suzhou) Biotechnology is recruiting adults with classic PKU into a phase 1/2 study of NGGT002, an AAV8 vector carrying functional human PAH. The company has reported preliminary investigator-initiated-study findings in eight patients, including Phe near 120 μmol/L for up to 32 weeks in five of six high-dose recipients; these results are preliminary, company-reported, and not yet a peer-reviewed demonstration of durable cure. NGGT002 phase 1/2 registry record NGGT002 company pipeline update (ichgcp.net)

Sanofi’s SAR444836 is another AAV-PAH gene-transfer program designed as a phase 1/2 dose-escalation and expansion study in 32 adults, with Phe control, dietary protein intake, vector shedding, and safety among the planned measures. SAR444836 trial summary Sanofi rare-disease pipeline overview (hra.nhs.uk) By contrast, Synlogic discontinued its phase 3 SYNPHENY-3 trial of the engineered probiotic SYNB1934 in February 2024 after an internal review indicated the study was unlikely to meet its primary efficacy endpoint, although the decision was not attributed to safety or tolerability concerns. Synlogic discontinuation announcement (globenewswire.com)

Methodologies and Scientific Approaches

Researchers use several complementary models: conventional Pahenu2 PKU mice, mice engineered to carry specific human PAH variants, edited human liver-cell lines, and increasingly larger-animal models. These systems allow investigators to measure whether a therapy restores PAH enzyme activity, lowers blood Phe, normalizes the Phe:tyrosine ratio, improves pigmentation or neurologic features, and maintains correction after treatment. State-of-the-art gene therapy review mRNA–lipid nanoparticle base editing (pubmed.ncbi.nlm.nih.gov)

The main delivery platforms are AAV vectors for long-lasting gene expression, lipid nanoparticles for transient mRNA or gene-editor delivery, and engineered gut bacteria that consume Phe before it reaches the bloodstream. Editing studies assess on-target correction, unintended “bystander” DNA changes near the target, potential off-target edits elsewhere in the genome, liver distribution, and durability; clinical gene-transfer trials add immune monitoring, liver-enzyme testing, vector shedding, diet records, and repeated blood-Phe measurements. mRNA–lipid nanoparticle base editing SAR444836 trial summary (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major academic contributors include Oregon Health & Science University, the University of Zurich and University Children’s Hospital Zurich, and the University of Pennsylvania and Children’s Hospital of Philadelphia. Their work spans AAV gene transfer, liver-directed CRISPR editing, disease modeling, and metabolic clinical care. State-of-the-art gene therapy review Rapid corrective editing in PKU mice (pubmed.ncbi.nlm.nih.gov) Industry participants include BioMarin, Sanofi, NGGT, Arcturus, Moderna, and PTC Therapeutics. BMN 307 trial record Moderna mRNA-3210 preclinical study APHENITY phase 3 trial (clinicaltrials.gov)

Patient-led funding remains important for early research. The National PKU Alliance’s 2024 research program described an average award of $50,000 for one-year pilot projects, with priorities including preclinical models, biomarkers, psychological and neurocognitive effects, and strategies that could lead to improved management or a cure. National PKU Alliance 2024 research call (npkua.org)

Strengths, Limitations, and Challenges

PKU is unusually attractive for genetic treatment because the disease mechanism is well defined, the primary target organ is the liver, and blood Phe provides a direct, quantitative biomarker of benefit. The fact that partial restoration of PAH activity can substantially improve Phe control means therapies may not need to correct every liver cell. State-of-the-art gene therapy review AAV prime editing of PKU variant (pubmed.ncbi.nlm.nih.gov)

The central barriers are substantial. AAV gene addition may fade as hepatocytes divide, especially in growing children, and pre-existing or treatment-induced immunity can limit eligibility and make repeat dosing difficult. Gene editors must show acceptable off-target and bystander-editing profiles, while variant-specific editors may not serve people with rarer PAH mutations. mRNA may be more reversible but likely requires repeated dosing, and the SYNB1934 experience shows that promising metabolic engineering in early trials does not guarantee phase 3 efficacy. State-of-the-art gene therapy review mRNA–lipid nanoparticle base editing Synlogic discontinuation announcement (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

A true cure for PKU is not yet close enough to promise on a specific timetable, but the path is clearer than it was in 2020: human AAV gene-transfer trials are underway, gene editing has normalized Phe in multiple mouse systems, and non-curative medicines are improving dietary freedom for some patients. The most important milestones to watch are peer-reviewed outcomes from AAV trials, sustained normal or near-normal Phe without strict dietary restriction, multi-year safety and durability data, successful re-dosing strategies, and the first clinical translation of liver-targeted base or prime editing. NGGT002 phase 1/2 registry record mRNA–lipid nanoparticle base editing AAV prime editing of PKU variant (ichgcp.net)

References

Don't see your disease? Request a report